美国Apexigen  www.apexigen.com
Apexigen是一家位于美国湾区的专注于治疗性抗体的研发和市场化的生物制药公司，广泛与国内外著名的生物制药及生物技术公司如美国强声、诺华制药、先声药业，三生制药等开展合作，拥有一流的抗体技术平台及丰富的产品线，包括用于治疗癌症及炎症的7个人源化兔单克隆抗体等。

Apexigen is a biopharmaceutcal company focused on discovering and developing best-in-class drugs from its proprietary monoclonal antibody technology platforms. Monoclonal antibodies specifically target cells or proteins that are essential components of diseases processes and activate the body’s immune system to remove or neutralize proteins and cells that cause or perpetuate disease.

Apexigen’s technology takes advantage of the extensive diversity in antibody specificity that is produced by the rabbit’s immune system. From this variety, very high affinity antibodies can be identified which have very exacting specificity and unique epitopes for disease targets. Such antibodies may have increased potency, efficacy and disease modifying ability.

Apexigen’s proprietary antibody technologies produce efficient capture of the rabbit’s innate antibody-making capability into stable, efficient hybridomas. Such stable hybridomas allow us to screen millions of individual antibodies and to select antibodies with optimal characteristics for drug development. The MLG humanization technology enables us to replace components of the rabbit monoclonal antibody with amino acid sequences that are commonly found in human antibodies. Humanization minimizes the possibility that patients will have immune or allergic reactions to treatment with the monoclonal antibody drug.

Apexigen was spun-out from Epitomics, Inc. in July of 2010. Apexigen has an exclusive, worldwide license to monoclonal antibody technologies developed by Epitomics for use in the development and commercialization of therapeutic antibodies. Epitomics will continue to utilize the technology to develop and commercialize rabbit antibodies for non-therapeutic uses.
Mission:

At Apexigen, our mission is to develop best-in-class antibody therapeutics for the treatment of human diseases with unmet medical needs.
Strategy:

Apexigen’s goal is to develop best-in-class antibody therapeutics. We will do that in two ways. We will collaborate with other pharmaceutical and biotechnology companies to utilize our technology platform to develop drugs against disease targets of interest to our partners while we at the same time discovering and developing our own pipeline of drugs.